Physician profile
Timothy Shew
NPI 1760014757
$2,050.52
in general payments reported to CMS, 2019-2025
31 companies · $627 in 2025
The $627 reported for 2025 was more than what 75% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $99.99 · 2022: $415 · 2023: $370 · 2024: $539 · 2025: $627.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,479 · Education: $56.24.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,478.97 |
| Education | $56.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $245.35 | 2022-2025 | Rybrevant, Carvykti, Darzalex |
| Janssen Scientific Affairs, LLC | $192.37 | 2022-2023 | Carvykti |
| Daiichi Sankyo INC. | $144.72 | 2024 | Enhertu |
| Seagen INC. | $139.25 | 2022-2023 | Padcev |
| Pfizer INC. | $137.69 | 2023-2025 | |
| Karyopharm Therapeutics INC. | $122.38 | 2022-2024 | Xpovio |
| E.R. Squibb & Sons, L.L.C. | $120.20 | 2022-2025 | Opdualag, Opdivo |
| Genentech USA, INC. | $101.98 | 2022-2025 | Venclexta, Phesgo, Kadcyla |
| Incyte Corporation | $99.99 | 2021 | |
| Genzyme Corporation | $94.37 | 2022-2025 | |
| Astellas Pharma US INC | $77.19 | 2025 | Vyloy |
| Pharmacosmos Therapeutics INC. | $73.62 | 2023-2025 | Monoferric |
| Abbvie INC. | $65.27 | 2024-2025 | |
| Eisai INC. | $51.40 | 2023-2025 | |
| Rigel Pharmaceuticals, INC. | $43.28 | 2025 | Gavreto, Rezlidhia, Tavalisse |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Octapharma USA, INC. | $42.44 | 2024 | Octagam Immune Globulin (Human) |
| Coherus Oncology, INC. | $38.81 | 2025 | Loqtorzi |
| Takeda Pharmaceuticals U.S.A., INC. | $36.31 | 2024 | Hyqvia |
| Servier Pharmaceuticals LLC | $21.09 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $20.17 | 2022 | |
| Tolmar, INC. | $20.14 | 2023 | |
| Aveo Pharmaceuticals, INC. | $20.00 | 2024 | |
| Caris Mpi, INC. | $17.95 | 2025 | Mi Cancer Seek |
| Kyowa Kirin, INC. | $17.91 | 2024 | Poteligeo |
| Pharmaessentia USA Corporation | $16.07 | 2024 | Besremi |
| Novartis Pharmaceuticals Corporation | $16.06 | 2024 | |
| Myriad Genetic Laboratories, INC. | $15.16 | 2024 | Myrisk |
| Blueprint Medicines Corporation | $15.07 | 2023 | Ayvakit |
| Amgen INC. | $14.94 | 2022 | |
| Tersera Therapeutics LLC | $14.79 | 2022 | |
| G1 Therapeutics, INC. | $14.55 | 2023 | Cosela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Shew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.